@MylesMcNulty@avacta Brilliant idea myles, can you ask if you can be permanently involved in some way in investor communications ?
I'm sure a fair few investors would support that idea
#AVCT
Avacta is pleased to provide detailed pre-clinical, clinical and pharmacokinetic data from the Phase 1a dose escalation study of its lead pre|CISION programme, AVA6000, a tumour activated form of doxorubicin. https://t.co/OWNtJyHfvQ #AVCT
In less than a month Memorial Sloan Kettering Cancer Library lists the number of articles containing ava6000 has increased from 81 to 272, looks like news is spreading in the states #avct
81 articles/resources in Memorial Sloan Kettering cancer library when searching ava6000, nice also to see the first one peer reviewed #avct
https://t.co/hDxCEEobqf